Johanna Mercier, serving as the Chief Communications & Corporate Affairs Officer at Gilead Sciences, Inc. (NASDAQ:GILD), has completed a sale of 3,000 shares of common stock on June 15, 2026. The transaction was formally disclosed through a recent Form 4 filing submitted to the Securities and Exchange Commission. The aggregate value of the disposed shares reached $371,762. Execution prices for the shares ranged from $123.4166 to $125.4 per unit. At the time of reporting, the stock was trading at $127.23, reflecting an approximate 18% gain over the trailing twelve-month period.
The sales were conducted in accordance with a Rule 10b5-1 trading plan, which Mercier established on February 20, 2025. Post-transaction, her direct ownership of Gilead Sciences common stock stands at 124,234 shares. Gilead Sciences has been assigned a "GREAT" Financial Health score by InvestingPro. The stock is currently trading below its calculated Fair Value, a metric that positions it within the undervalued segment of its sector. Fundamental metrics include a Price-to-Earnings ratio of 17.25 and a Price/Earnings-to-Growth ratio of 0.31.
In parallel with the executive transaction, Gilead Sciences announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for Yeztugo. Yeztugo is formulated as a 300-mg tablet designed for once-weekly oral HIV prevention. The regulatory agency has established a target action date of February 2, 2027, for the review of this application. The submission is underpinned by clinical data from the PURPOSE 1 and PURPOSE 2 trials, which evaluated lenacapavir across diverse patient populations.
Furthermore, Gilead Sciences and Merck jointly reported positive outcomes from the Phase 3 ISLEND-1 and ISLEND-2 clinical trials. These studies focused on a once-weekly HIV treatment and successfully met their primary efficacy endpoints. Cantor Fitzgerald recently reiterated an Overweight rating on Gilead Sciences, maintaining a price target of $155.00. The firm cited the significance of the positive trial results for the company's HIV treatment portfolio as a key factor in its analysis.
Beyond its commercial pipeline, Gilead Sciences has engaged in humanitarian efforts, donating over 2,000 vials of remdesivir to Uganda to assist in the response to an Ebola Bundibugyo virus outbreak. The company is coordinating with the Democratic Republic of the Congo and the World Health Organization to supply additional antiviral agents. Detailed analysis of Gilead Sciences is available through its comprehensive Pro Research Report, which is accessible alongside data for over 1,400 other US equities.